Lobe Sciences Ltd. announced that Baxter F. Phillips III has been appointed to the Board of Directors of the Company, effective October 3, 2022. Mr. Phillips has more than 20 years of experience leading multinational corporate strategy and finance in the biotechnology and pharmaceutical industry. As a member of the Company's Board of Directors, Mr. Phillips will also serve as the Chairman of the Audit Committees.

Most recently, Baxter was Chief Executive Officer of UK based Camallergy where he continues to serves as an independent director. Prior to Camllergy, Mr. Phillips was CEO of Neurogastrx, where he successfully led the company to its transformational $45 million Series A financing. Prior to Neurogastrx, Mr. Phillips served as Chief Business Officer of AmpliPhi Biosciences (now Armata Pharmaceuticals: ARMP), where he played a pivotal role in establishing manufacturing, leading multiple financing campaigns and navigating the company to its NYSE listing.

Prior to AmpliPhi, Baxter's leadership appointments included Depomed, where he was responsible for licensing the product portfolio of development-stage and marketed products on a global basis, and Osteologix, where he successfully concluded a global licensing transaction with a multinational pharmaceutical company. Mr. Phillips began his career as a research scientist with Insmed (INSM). where for ten years he held a range of leadership positions in research, licensing, finance, investor relations, and sales and marketing.

He earned his MBA from the College of William and Mary and his Bachelor of Science in Biology from Hampden-Sydney College.